MENU
+Compare
KTTA
Stock ticker: NASDAQ
AS OF
Jun 13 closing price
Price
$0.79
Change
-$0.04 (-4.82%)
Capitalization
5.85M

KTTA stock forecast, quote, news & analysis

Pasithea Therapeutics Corp is a biotechnology company... Show more

KTTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for KTTA with price predictions
Jun 13, 2025

KTTA in downward trend: 10-day moving average moved below 50-day moving average on May 13, 2025

The 10-day moving average for KTTA crossed bearishly below the 50-day moving average on May 13, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 02, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on KTTA as a result. In of 69 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KTTA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for KTTA entered a downward trend on June 06, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for KTTA's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for KTTA just turned positive on May 29, 2025. Looking at past instances where KTTA's MACD turned positive, the stock continued to rise in of 37 cases over the following month. The odds of a continued upward trend are .

KTTA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.451) is normal, around the industry mean (16.954). P/E Ratio (0.000) is within average values for comparable stocks, (59.376). KTTA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.335). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (257.043).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. KTTA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KTTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.45B. The market cap for tickers in the group ranges from 31.65 to 355.9B. NONOF holds the highest valuation in this group at 355.9B. The lowest valued company is CYCCP at 31.65.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -1%. For the same Industry, the average monthly price growth was 13%, and the average quarterly price growth was 4%. KLTO experienced the highest price growth at 680%, while LYRA experienced the biggest fall at -53%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -37%. For the same stocks of the Industry, the average monthly volume growth was -52% and the average quarterly volume growth was 43%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 58
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: 10 (-100 ... +100)
View a ticker or compare two or three
KTTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1111 Lincoln Road
Phone
+1 702 514-4174
Employees
8
Web
https://www.pasithea.com